How Retatrutide Works: Mechanism of Action in the Published Research

The short answer

Retatrutide is an investigational peptide designed as a single molecule that binds and activates three different hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. Published trial reports describe it in exactly those terms — a “triple-hormone-receptor agonist” evaluated in people with obesity (PMID 37366315) and as a “GIP, GLP-1 and glucagon receptor agonist” evaluated in people with type 2 diabetes (PMID 37385280). The design rationale, as summarised in a 2025 review, is that combining incretin receptor activity with glucagon receptor activity engages both sides of the energy balance equation rather than appetite alone (PMID 40563436).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, including whether any investigational or prescription medicine is appropriate. Retatrutide is a prescription-pathway drug candidate under clinical investigation, not a consumer product, and questions about its use belong with a prescribing clinician.

Three receptors, one peptide

Each of the three receptors retatrutide targets is a G-protein-coupled receptor that normally responds to a different endogenous hormone. The following descriptions summarise the conventional endocrinology of each receptor; the trial findings that follow in later sections are the part attributable to specific studies.

The GLP-1 receptor

GLP-1 is an incretin hormone released from intestinal L-cells after eating. Its receptor is expressed on pancreatic beta cells, in regions of the hypothalamus and brainstem that regulate appetite and satiety, and in the gastrointestinal tract. Activation is classically associated with glucose-dependent insulin secretion, suppression of glucagon release when glucose is elevated, slowed gastric emptying and reduced food intake. This is the best-characterised of the three arms, because drugs acting only at this receptor have been studied for years; a 2025 Bayesian network meta-analysis compared retatrutide directly against single-receptor GLP-1 agonists and dual agonists in adults with overweight or obesity (PMID 40685589).

The GIP receptor

GIP is the other major incretin, released from intestinal K-cells. Its receptor sits on beta cells, on adipocytes and in central nervous system regions involved in food intake and nausea signalling. In the pancreas, GIP receptor activation contributes to glucose-dependent insulin release. In adipose tissue it is linked to nutrient handling and lipid storage, and in the brain it has been proposed to modulate appetite and the tolerability of incretin therapy. The direction of benefit from GIP receptor pharmacology — agonism versus antagonism — remains an area of active debate in the field, and retatrutide sits on the agonist side of that question (PMID 40563436).

The glucagon receptor

Glucagon receptors are concentrated in the liver, with additional expression in kidney, heart and adipose tissue. Hepatic glucagon receptor activation is associated with glycogenolysis, gluconeogenesis, increased fatty acid oxidation and increased energy expenditure. Adding glucagon receptor agonism to a weight-management molecule is therefore a trade-off: it introduces a pathway that could raise glucose output from the liver, which the incretin components are intended to offset. A 2023 expert commentary framed retatrutide's combination as a deliberate attempt to capture the energy-expenditure side of glucagon biology while incretin signalling handles glycaemic control (PMID 37947489).

Established mechanism versus proposed mechanism

It is worth separating what the published human literature actually demonstrates from what is inferred about the underlying biology.

How the combination is proposed to act downstream

The working model described in reviews of retatrutide splits its effects into two broad channels (PMID 40563436):

• Reduced energy intake. GLP-1 and GIP receptor signalling in hypothalamic and brainstem circuits, together with slowed gastric emptying, is the conventional explanation for lower food intake with incretin-based drugs.
• Increased energy expenditure and hepatic lipid handling. Glucagon receptor signalling in the liver is the proposed route for increased fatty acid oxidation and higher resting energy expenditure, and is the component most often invoked to explain liver-fat findings.
• Glycaemic balance. Incretin-driven, glucose-dependent insulin secretion is proposed to counterbalance the hepatic glucose output that glucagon receptor agonism would otherwise favour, which is why glycaemic outcomes in diabetes trials are treated as a mechanistic test of the design (PMID 37385280).

Note what is missing from this page: cell-based receptor binding assays and rodent pharmacology. Those experiments exist in the wider literature but are not among the papers verified for this page, so no in-vitro potency ratios or animal findings are quoted here. Everything cited below is human clinical research or a review of it.

What human trials have reported that bears on mechanism

Body weight

In a 48-week phase 2 trial in adults with obesity, researchers reported a least-squares mean change in body weight of −24.2% in the highest-dose group compared with −2.1% with placebo, with smaller changes in lower-dose groups (PMID 37366315). A 2026 phase 3 report in the same journal subsequently evaluated retatrutide for the treatment of obesity (PMID 42814954). A 2025 systematic review and meta-analysis of randomised controlled trials pooled the available obesity data and examined both efficacy and safety signals across dose groups (PMID 40291085), and a separate 2025 systematic review of clinical trials reached a similar descriptive conclusion about dose-dependence (PMID 40728138).

Glycaemic control

A phase 2 trial in people with type 2 diabetes compared retatrutide against both placebo and the GLP-1 receptor agonist dulaglutide 1.5 mg and reported reductions in glycated haemoglobin across retatrutide dose groups (PMID 37385280). The phase 3 TRANSCEND-T2D-1 trial then assessed efficacy and safety in people with type 2 diabetes whose glycaemic control was inadequate with diet and exercise alone (PMID 42250575). From a mechanistic standpoint, these glycaemic results are the data most often read as evidence that incretin receptor activity offsets the glucagon receptor arm rather than being overwhelmed by it.

Liver fat

A randomised phase 2a trial in metabolic dysfunction-associated steatotic liver disease reported reductions in liver fat content with retatrutide relative to placebo (PMID 38858523). Because the liver is where glucagon receptors are most densely expressed, hepatic findings are frequently treated as the most direct available human signal of the glucagon arm — although weight loss itself also reduces liver fat, so the study design cannot cleanly separate the two routes.

Body composition

A substudy of a phase 2 trial in people with type 2 diabetes used imaging to examine how weight change was distributed, and the researchers reported reductions in fat mass alongside smaller changes in lean mass (PMID 40609566). Body-composition data of this kind are relevant to mechanism because an energy-expenditure component would be expected to show up in the composition of tissue lost, not only in total kilograms.

Trials still reporting

The TRIUMPH programme was designed as a set of registrational trials covering obesity, obstructive sleep apnoea and knee osteoarthritis, and its rationale and design have been published (PMID 41090431). Those trials extend the evidence base into conditions where mechanism is less about receptor pharmacology and more about downstream consequences of metabolic change.

Adverse Events: What Studies Report

Mechanism and tolerability are linked, because the gastrointestinal and central effects of incretin receptor activation are also where most reported adverse events cluster. In the 48-week phase 2 obesity trial, the most common adverse events were gastrointestinal, were mostly mild to moderate, and occurred in a dose-related pattern (PMID 37366315). The phase 2 type 2 diabetes trial likewise reported gastrointestinal adverse events as the most frequent category (PMID 37385280), and a 2025 systematic review and meta-analysis found a higher rate of gastrointestinal adverse events with retatrutide than with placebo across pooled randomised trials (PMID 40291085). A further 2025 systematic review of clinical trials summarised the safety profile reported to date (PMID 40728138). Assessment of whether any of this is relevant to an individual is a clinical matter, not something a general information page can address.

Regulatory status, stated plainly

Retatrutide has been studied through phase 2 and into phase 3 registrational trials (PMID 41090431, PMID 42250575). It is an investigational medicine evaluated under clinical trial conditions with medical supervision. Material sold outside a pharmacy supply chain is not the same thing as the molecule studied in these trials, and no part of this page should be read as describing how anyone might use it. Any question about eligibility, suitability or alternatives belongs with a licensed prescribing clinician.

What the mechanism literature still cannot say

1. Receptor attribution. Because all three activities travel on one molecule, no cited human trial can state how much of a given result came from the GIP, GLP-1 or glucagon arm.
2. Long-term physiology. The cited trials report defined periods of follow-up; durability of mechanism-level effects beyond those windows was not established by them.
3. Population generalisability. Mechanistic inferences drawn from trial populations with obesity, type 2 diabetes or steatotic liver disease do not automatically extend to other groups (PMID 40728138).
4. Comparative positioning. Indirect comparisons against other incretin drugs come from network meta-analysis rather than head-to-head mechanistic studies (PMID 40685589).

Related reading

For a broader overview of the compound, its trial programme and its regulatory position, see the retatrutide learn page.

References

• Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial (The New England Journal of Medicine, 2023)
• Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (Lancet, 2023)
• Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1) (Lancet, 2026)
• Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (The New England Journal of Medicine, 2026)
• Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial (Nature Medicine, 2024)
• Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 randomised trial (The Lancet Diabetes & Endocrinology, 2025)
• Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials (Diabetes, Obesity & Metabolism, 2026)
• Retatrutide-A Game Changer in Obesity Pharmacotherapy (Biomolecules, 2025)
• Retatrutide showing promise in obesity (and type 2 diabetes) (Expert Opinion on Investigational Drugs, 2023)
• Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials (Proceedings (Baylor University Medical Center), 2025)
• Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA (Obesity, 2025)
• Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials (Journal of Basic and Clinical Physiology and Pharmacology, 2025)